Intravenous Immunoglobulin Market - By Product (IGG, IGA, IGM, IGD, IGE), Application (Hypogammaglobulinemia, CIDP, Immunodeficiency diseases, Myasthenia Gravis, MMN, ITP), Distribution Channel (Hospital, Specialty), Global Forecast, 2023

Description

List of Tables

Global Intravenous Immunoglobulin Market size could exhibit 7.6% CAGR from 2023 to 2032, driven by the rise in the aging population. According to IMF projections, global life expectancy has shown remarkable progress, rising from just 34 years in 1913 to 72 years in 2022, and this upward trend is expected to persist over the long term. Similarly, data from the 2019 Revision of World Population Prospects reveals that by 2050, the proportion of people aged over 65 in the world will increase to one in six (16%), up from one in eleven (9%) in 2019. Furthermore, by 2050, as many as one in four individuals in Europe and Northern America may be 65 or older.

As people age, their immune systems may weaken, making them more susceptible to various diseases and conditions. IVIG is a crucial treatment for various autoimmune and immunodeficiency disorders. With a growing elderly demographic worldwide, the demand for IVIG as a therapeutic option is increasing, creating a favorable environment for market expansion and growth.

The overall Intravenous Immunoglobulin Market is categorized based on product, application, distribution channel, and region.

IgE Intravenous Immunoglobulin Industry will garner a noteworthy valuation by 2032 due to the specific role of IgE Intravenous Immunoglobulin in treating severe allergic conditions and anaphylactic reactions. As allergies become more prevalent, especially in developed nations, there's a growing need for effective allergy management and treatment. IgE immunoglobulin provides targeted relief for those experiencing life-threatening allergic responses, making it a vital component in managing severe allergies and anaphylaxis, thus driving its demand.

Intravenous immunoglobulin market share from the Myasthenia Gravis segment will grow commendably over 2023-2032 due to the high demand for IVIG in the treatment of Myasthenia Gravis owing to its immunomodulatory effects. Myasthenia Gravis is an autoimmune neuromuscular disorder where the immune system attacks neuromuscular junctions, leading to muscle weakness. IVIG therapy helps to modulate the immune response and alleviate symptoms. As the prevalence of autoimmune diseases like Myasthenia Gravis continues to rise, the demand for IVIG as a treatment option has increased.

Asia Pacific intravenous immunoglobulin (IVIG) industry is expanding due to multiple factors. Increasing healthcare infrastructure, rising awareness of IVIG therapies, and a growing aging population have contributed to the region's increased demand for immunoglobulin products. Moreover, a surge in autoimmune and immunodeficiency disorders in the region necessitates IVIG treatment. As healthcare access improves and awareness spreads, the Asia Pacific region offers significant growth opportunities for the IVIG industry.

Product Code: 6491

Chapter 1 Methodology & Scope

1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Forecast parameters
1.4 COVID-19 impact analysis
1.5 Data validation
1.6 Data Sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

2.1 Intravenous immunoglobulin industry 360 degree synopsis, 2018 - 2032
- 2.1.1 Business trends
- 2.1.2 Regional trends
- 2.1.3 Product trends
- 2.1.4 Application trends
- 2.1.5 Distribution channel trends

Chapter 3 Intravenous Immunoglobulin Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Growing prevalence of immunodeficiency disorders
  - 3.2.1.2 Increasing geriatric population
  - 3.2.1.3 Growing advances in plasma collection, fractionation, and purification technologies
  - 3.2.1.4 Increasing healthcare expenditure for immunoglobulins
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of IVIG therapy
  - 3.2.2.2 Potential adverse effects and allergic reactions
  - 3.2.2.3 Scarcity of plasma donors
3.3 Growth potential analysis
- 3.3.1 By product
- 3.3.2 By application
- 3.3.3 By distribution channel
3.4 COVID- 19 impact analysis
3.5 Porter's analysis
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players, 2022
4.4 Competitive positioning matrix, 2022
4.5 Strategy dashboard, 2022

Chapter 5 Intravenous Immunoglobulin Market Size and Forecast, By Product (USD Million)

5.1 Key trends, by product
5.2 IgG
5.3 IgA
5.4 IgM
5.5 IgD
5.6 IgE

Chapter 6 Intravenous Immunoglobulin Market Size and Forecast, By Application (USD Million)

6.1 Key trends, by application
6.2 Hypogammaglobulinemia
6.3 Chronic Inflammatory demyelinating polyneuropathy (CIDP)
6.4 Immunodeficiency diseases
6.5 Myasthenia gravis
6.6 Multifocal motor neuropathy
6.7 Idiopathic thrombocytopenic purpura (ITP)
6.8 Inflammatory myopathies
6.9 Specific antibody deficiency
6.10 Guillain-Barre syndrome
6.11 Other applications

Chapter 7 Intravenous Immunoglobulin Market Size and Forecast, By Distribution Channel (USD Million)

7.1 Key trends, by distribution channel
7.2 Hospital pharmacy
7.3 Specialty pharmacy
7.4 Other distribution channels

Chapter 8 Intravenous Immunoglobulin Market Size and Forecast, By Region (USD Million)

8.1 Key trends, by region
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Rest of Europe
8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East & Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 Rest of Middle East & Africa

Chapter 9 Company Profiles

9.1 Takeda Pharmaceutical Company Limited.
9.2 Grifols SA
9.3 CSL Behring
9.4 ADMA Biologics
9.5 Octapharma AG
9.6 Baxter International Inc.
9.7 LFB Biotechnologies
9.8 China Biologics Products Inc.
9.9 Kedrion Biopharma
9.10 Intas Pharmaceuticals